Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.72 Analyst target: $7.30 Upside: 54.66%
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA modifications. The firm has curated a diverse pipeline targeting severe diseases, including genetic disorders and various cancers, addressing substantial unmet medical needs within the healthcare system. With a strong intellectual property foundation and a commitment to developing innovative therapeutic solutions, Prime Medicine is strategically positioned for notable growth and has the potential to significantly change therapeutic approaches in the biopharmaceutical industry.
See the full interactive analysis & chart →Informational only — not investment advice.